For many years Tardive Dyskinesia (TD) has been considered a side effect of antipsychotic medicines, and one of the wider group of Extra-Pyramidal Side Effects (EPSE). However, in the last decade, after studying of it in psychiatric training, it is little or never discussed in day to day clinical practice. It has been presumed that newer antipsychotics have reduced or eliminated TD. This is not true.
The recent development and launch of effective and tolerable psychopharmacological treatments for TD in other parts of the world have stimulated renewed interest in TD that was, in many respects, lost to history.
This has included:
- New research that seeks to identify the true prevalence of TD which is felt to be rarely diagnosed in clinical practice, even when seen
- The publication of new national guidelines for its management
- An innovative TD registry providing much needed information about the multifactorial impact of TD on those which have this condition.
Given that TD is usually irreversible, permanent and compounds the stigma of having an underlying mental illness, it may be better to start to view TD as a condition in of its own right, and not just a side effect.
This session will provide an update on this topic, with perspectives from researchers and clinicians who work in a range of services, and who work with a diverse range of patient cohorts. It will set out the likely true prevalence of TD, how it can be best diagnosed, and attendees will be directed to high quality publications that set out the evidence base and practicalities of TD management. To ensure a rounded presentation we will also present videos from experts by experience and charities such as Bipolar UK on the health burden of TD and need for change from patient perspectives.
Learning objectives
By attending this session you will:
- Gain understanding of the true prevalence of Tardive Dyskinesia (TD)
- Feel more confident in the diagnosis of TD
- Hear a range of diverse perspectives of TD and its impact on different patient groups
- Be able to identify international sources of guidance on the management of TD.
Speakers
Chair: Professor Rohit Shankar, University of Plymouth Peninsula Medical School, Truro
Dr Rashmi Patel, University of Cambridge, Cambridge
Dr Julie Hankin, Leeds and York Partnership NHS Foundation Trust, Leeds
Dr Chinyere Iheonu, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham
Availability
This webinar is part of the Congress webinar 2025 package. If you attended all four days of Congress, you will have access to these as part of your Congress package. Otherwise the Congress webinar 2025 package can be purchased below.
